InMode Ltd. (NASDAQ:INMD) Given Average Rating of “Hold” by Analysts

InMode Ltd. (NASDAQ:INMD) has been given an average recommendation of “Hold” by the six research firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $32.80.

A number of analysts have recently weighed in on INMD shares. Barclays dropped their target price on shares of InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, April 12th. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a report on Tuesday, April 9th. Finally, UBS Group lifted their price objective on InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Exchange Traded Concepts LLC purchased a new position in InMode during the third quarter valued at $27,000. Principal Securities Inc. purchased a new stake in InMode in the fourth quarter worth about $32,000. Carmel Capital Partners LLC purchased a new stake in InMode in the third quarter worth about $36,000. Sunbelt Securities Inc. bought a new position in shares of InMode during the third quarter valued at approximately $47,000. Finally, Trust Co. of Vermont lifted its holdings in shares of InMode by 32.8% during the fourth quarter. Trust Co. of Vermont now owns 2,168 shares of the healthcare company’s stock valued at $48,000 after purchasing an additional 536 shares during the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Trading Up 0.7 %

NASDAQ INMD opened at $17.14 on Friday. The firm has a market cap of $1.44 billion, a PE ratio of 7.45 and a beta of 2.16. InMode has a 1-year low of $16.82 and a 1-year high of $48.25. The stock has a 50-day moving average of $20.32 and a 200-day moving average of $21.54.

InMode (NASDAQ:INMD) last issued its earnings results on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. InMode had a net margin of 40.22% and a return on equity of 29.80%. The company had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.69 earnings per share. As a group, equities research analysts forecast that InMode will post 2.04 earnings per share for the current fiscal year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.